Suzanne Nielsen1,2, Nadia Menon1, Sarah Larney1, Michael Farrell1, Louisa Degenhardt1. 1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia. 2. Drug and Alcohol Services, South Eastern Sydney Local Health District, Surry Hills, NSW, Australia.
Abstract
AIM: Given the potential to expand naloxone supply through community pharmacy, the aim of this study was to estimate Australian pharmacists': (1) level of support for overdose prevention, (2) barriers and facilitators for naloxone supply and (3) knowledge about naloxone administration. DESIGN: Online survey from nationally representative sample of community pharmacies. SETTING: Australia, September-November 2015. PARTICIPANTS: A total of 1317 community pharmacists were invited to participate with 595 responses (45.1%). MEASUREMENTS: We assessed attitudes towards harm reduction, support for overdose prevention, attitudes and knowledge about naloxone. We tested the association between attitudes towards harm reduction and different aspects of naloxone supply. FINDINGS: Pharmacists were willing to receive training about naloxone (n = 479, 80.5%) and provide naloxone with a prescription (n = 537, 90.3%). Fewer (n = 234, 40.8%) were willing to supply naloxone over-the-counter. Positive attitudes towards harm reduction were associated with greater willingness to supply naloxone with a prescription [odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.11-1.19] and over-the-counter (OR = 1.13, 95% CI = 1.09-1.17). Few pharmacists were confident they could identify appropriate patients (n = 203, 34.1%) and educate them on overdose and naloxone use (n = 190, 31.9%). Mean naloxone knowledge scores were 1.8 (standard deviation 1.7) out of 5. More than half the sample identified lack of time, training, knowledge and reimbursement as potential barriers for naloxone provision. CONCLUSION: Community pharmacists in Australia appear to be willing to supply naloxone. Low levels of knowledge about naloxone pharmacology and administration highlight the importance of training pharmacists about overdose prevention.
AIM: Given the potential to expand naloxone supply through community pharmacy, the aim of this study was to estimate Australian pharmacists': (1) level of support for overdose prevention, (2) barriers and facilitators for naloxone supply and (3) knowledge about naloxone administration. DESIGN: Online survey from nationally representative sample of community pharmacies. SETTING: Australia, September-November 2015. PARTICIPANTS: A total of 1317 community pharmacists were invited to participate with 595 responses (45.1%). MEASUREMENTS: We assessed attitudes towards harm reduction, support for overdose prevention, attitudes and knowledge about naloxone. We tested the association between attitudes towards harm reduction and different aspects of naloxone supply. FINDINGS: Pharmacists were willing to receive training about naloxone (n = 479, 80.5%) and provide naloxone with a prescription (n = 537, 90.3%). Fewer (n = 234, 40.8%) were willing to supply naloxone over-the-counter. Positive attitudes towards harm reduction were associated with greater willingness to supply naloxone with a prescription [odds ratio (OR) = 1.15, 95% confidence interval (CI) = 1.11-1.19] and over-the-counter (OR = 1.13, 95% CI = 1.09-1.17). Few pharmacists were confident they could identify appropriate patients (n = 203, 34.1%) and educate them on overdose and naloxone use (n = 190, 31.9%). Mean naloxone knowledge scores were 1.8 (standard deviation 1.7) out of 5. More than half the sample identified lack of time, training, knowledge and reimbursement as potential barriers for naloxone provision. CONCLUSION: Community pharmacists in Australia appear to be willing to supply naloxone. Low levels of knowledge about naloxone pharmacology and administration highlight the importance of training pharmacists about overdose prevention.
Authors: Aaron Salwan; Nicholas E Hagemeier; Fred Tudiver; KariLynn Dowling-McClay; Kelly N Foster; Jessie Arnold; Arsham Alamian; Robert P Pack Journal: J Am Pharm Assoc (2003) Date: 2020-07-12
Authors: Andrew S Bzowyckyj Chair; Brian Crabtree; Kari Franson; Donald Klepser; Arinzechukwu Nkemdirim Okere; Therese Poirier; Adam Welch; Nidhi Gandhi; Kelly Ragucci Journal: Am J Pharm Educ Date: 2020-10 Impact factor: 2.047
Authors: B E Meyerson; J D Agley; A Davis; W Jayawardene; A Hoss; D J Shannon; P T Ryder; K Ritchie; R Gassman Journal: Drug Alcohol Depend Date: 2018-04-26 Impact factor: 4.492